Compare TransMedics Group Inc (TMDX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Yum China Holdings Inc — how do they compare? TransMedics Group Inc trades at $86.4 (market cap $3.00B), while Yum China Holdings Inc trades at $42.55 (market cap $14.48B). The key difference: Yum China Holdings Inc is far larger — about 4.8× TransMedics Group Inc's market cap, and Yum China Holdings Inc pays a 2.72% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | YUMC | |
|---|---|---|
Market Cap | $3.00B | $14.48B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $57.95 |
52-Week Low | $61.99 | $40.18 |
Enterprise Value | $3.39B | $15.39B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
YUMC trades at $43.34, down 0.6% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $0.70 surpassing the $0.67 estimate. Revenue grew to $11.80 billion in 2025, and net income reached $929 million. Recent developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of the Pizza Hut Burger Bar to 300 locations.
The outlook remains positive given strong analyst support, with 14 buy ratings and a consensus pointing to 25.6% upside. Key risks include execution of expansion plans and macroeconomic pressures in China. The stock presents a value opportunity with a P/E of 15.88 and solid profitability metrics, but investors should monitor competitive dynamics and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
